Conference abstract
Conference abstractPublished 2019
Blood coagulum-OMICS
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The NHS will be a world-leading healthcare organization to predict and diagnose inherited and acquired disease, and to personalize treatment and intervention. This program was designed to validate and quality manage the introduction of Blood Coagulum-OMICS and verify genomic, viscoelastic, and proteomic predictive value for hemostasis and thrombosis. Background: In 2014, a Patient Blood Management program was overseen by a national governance representative, sponsored by an anesthetic lead and edited by an MHRA inspector who stated “this program is suitable for the NHS”. In 2017, that program was posted to the hemostasis and thrombosis, National External Quality Assurance Scheme and then to the British Blood Transfusion Society, in the UK. Study: The conclusion read as “scientific specialists are now firmly planted in the realms of clinical effectiveness, interfacing clinicians on the governance board. We must now accelerate the PBM Quality Assurance network to control risk from genomic and proteomic explosions in personalized medicine. Quality assures our technological advances from end to end of the surgical examination phase and control our pharmacological breakthroughs in support of healthcare clinicians. Program Development: On the 4th of July 2017, Professor Dame Sally, the Chief Medical Officer of the UK called on the NHS to provide access to genomic sequencing, as standard. This followed studies that realised genome models to pre-empt a bleed or thrombotic event. Meanwhile coagulation and fibrinolysis elasticity reference ranges to monitor a clinical event or target a therapy are developing, at a time when coagulation proteomics have passed proof of concept. Conclusion: This second program on Blood Coagulum-OMICS was designed to stop the bleed and thrombotic event by improving the predictive value in pre-examination and examination phases. A program for Blood Coagulum-OMICS is a minimum standard for haemostasis and thrombosis and requires consideration by the International Organisation for Standardisation.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 30 Nov 2021
The model and guide for Blood coagulum-OMICS
Short communication · 30 Nov 2021
Personalized and Regeneration Medicine require a Coagulum-OMICs Model
Short communication · 2021
Biotechnology, Biomarkers & Systems Biology 2019: Personalized and Regeneration Medicine require a Coagulum-OMICs Model - James Andrew Henry - Atlantis BMS Limited
Conference abstract · 2019
Personalized and Regeneration Medicine require a Coagulum- OMICs Model
More from this journal
The newest in Annals of Clinical and Laboratory Research.
Commentary · 8 Oct 2025
Cardiometabolic Therapies at the Crossroads of Coronary Artery Disease
Mini review · 2 Oct 2025
Characteristics and Treatment of Juvenile Myasthenia Gravis
Commentary · 9 Jul 2025
Commentary on Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: Real-World Data from 134 Patients
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAnnals of Clinical and Laboratory Research
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “James Henry”

